CROSSWICKS, N.J.--(BUSINESS WIRE)--The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at the 13th annual Congress of the European Hematology Association (EHA) in Copenhagen, Denmark continues to demonstrate significant advances in the treatment of higher-risk patients with myelodysplastic syndromes (MDS). The data showed that treatment with azacitidine (VIDAZA) instead of conventional care regimens (CCR), such as chemotherapy with Ara-C, can help patients to live longer with a better quality of life.
